Antibodies to phosphatidylserine/prothrombin complex and the antiphospholipid syndrome

Lupus

Volumn 23, Issue 12, 2014, Pages 1309-1312

  Sciascia, S ^a,b   Bertolaccini, M L ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

anti phosphatidylserine; Antiphospholipid antibodies; antiphospholipid syndrome; antiprothrombin; stroke; thrombosis; venous thrombosis

Indexed keywords

BIOLOGICAL MARKER; LUPUS ANTICOAGULANT; PHOSPHATIDYLSERINE ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTHROMBIN COMPLEX ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; PHOSPHATIDYLSERINE; PROTHROMBIN;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE ASSOCIATION; HUMAN; IMMUNOPATHOGENESIS; LABORATORY DIAGNOSIS; PATIENT RISK; RISK FACTOR; TREND STUDY; BLOOD; IMMUNOLOGY; THROMBOSIS;

ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; HUMANS; LUPUS COAGULATION INHIBITOR; PHOSPHATIDYLSERINES; PROTHROMBIN; RISK FACTORS; THROMBOSIS;

EID: 84908660347     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314538332     Document Type: Conference Paper

References (31)

1. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000 ; 43: 1982-1993
2. Bertolaccini ML, Atsumi T, Koike T, Hughes GR, Khamashta MA. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost. 2005 ; 93: 289-297
3. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost. 1997 ; 77: 486-491
4. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other antiphospholipid autoantibodies. Blood. 1994 ; 84: 2854-2867
5. Vaarala O, Puurunen M, Manttari M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost. 1996 ; 75: 456-459
6. Bertolaccini ML, Atsumi T, Khamashta MA, Amengual O, Hughes GR. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol. 1998 ; 25: 1104-1108
7. Pengo V, Denas G, Bison E, et al. Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with lupus anticoagulant (LA). Thromb Res. 2010 ; 126: 150-153
8. Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Bertolaccini ML. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: Evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost. 2012 ; 10: 2512-2518
9. Sciascia S, Khamashta MA, Bertolaccini ML. New tests to detect antiphospholipid antibodies: Antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies. Curr Rheumatol Rep. 2014 ; 16: 415-415
10. Funke A, Bertolaccini ML, Atsumi T, Amengual O, Khamashta MA, Hughes GRV. Autoantibodies to prothrombin-phosphatidylserine complex: Clinical significance in systemic lupus erythematosus. Arthritis Rheum. 1998 ; 41: S240 - S240
11. Bertolaccini ML, Gomez S, Pareja J, et al. Antiphospholipid antibody tests: Spreading the net. Ann Rheum Dis. 2005 ; 64: 1639-1643
12. Tselios K, Sarantopoulos A, Gkougkourellas I, Boura P. The role of antiphosphatidylserine/prothrombin antibodies in thrombotic manifestations of systemic lupus erythematosus patients. Front Neurol. 2013 ; 4: 66-66
13. Zigon P, Cucnik S, Ambrozic A, et al. Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value. Clin Dev Immunol. 2013 ; 2013: 724592-724592
14. Sanfelippo M, Joshi A, Schwartz S, Meister J, Goldberg J. Antibodies to phosphatidylserine/prothrombin complex in suspected antiphospholipid syndrome in the absence of antibodies to cardiolipin or beta-2-glycoprotein I. Lupus. 2013 ; 22: 1349-1352
15. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014 ; 111: 354-364
16. Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood. 1988 ; 72: 512-519
17. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost. 1991 ; 66: 629-632
18. Permpikul P, Rao LV, Rapaport SI. Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood. 1994 ; 83: 2878-2892
19. Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism?. Blood. 1993 ; 81: 2618-2625
20. Atsumi T, Amengual O, Yasuda S, Koike T. Antiprothrombin antibodies - are they worth assaying?. Thromb Res. 2004 ; 114: 533-538
21. Pregnolato F, Chighizola CB, Encabo S, et al. Anti-phosphatidylserine/prothrombin antibodies: An additional diagnostic marker for APS?. Immunol Res. 2013 ; 56: 432-438
22. Bertolaccini ML, Sciascia S, Murru V, Garcia-Fernandez C, Sanna G, Khamashta MA. Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant. Thromb Haemost. 2013 ; 109: 207-213
23. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010 ; 8: 237-242
24. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005 ; 93: 1147-1152
25. Sciascia S, Cosseddu D, Montaruli B, Kuzenko A, Bertero MT. Risk scale for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis. 2011 ; 70: 1517-1518
26. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: A multicenter prospective study. Blood. 2011 ; 118: 4714-4718
27. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009 ; 302: 2345-2352
28. Collins GS, Moons KG. Comparing risk prediction models. BMJ. 2012 ; 344: e3186 - e3186
29. Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012 ; 64: 504-512
30. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: The Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 2013 ; 52: 1397-1403
31. Bertolaccini ML, Amengual O, Andreoli L, et al. 14-th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. Epub 10 May 2014. pii: S1568-9972(14)00120-7. DOI: 10.1016/j.autrev.2014.2014.05.001.